BPC-157 fully counteracts topical ophthalmic anesthetics, shortening corneal insensitivity in rats
Background
Topical ophthalmic anesthetics like tetracaine and oxybuprocaine are essential for many eye procedures, but they come with drawbacks, including delayed recovery of corneal sensitivity, increased risk of corneal lesions, and decreased tear production. Prolonged corneal insensitivity leaves the eye vulnerable to injury and dryness. A method to rapidly reverse these effects could improve patient safety and comfort post-procedure. The nitric oxide synthase (NOS) pathway is implicated in these ocular responses. This study investigates pentadecapeptide BPC-157, known for its tissue-protective and healing properties, as a potential counteracting agent to mitigate the adverse effects of these common topical anesthetics.
Study Design
This was a preclinical animal study in rats. Investigators induced corneal anesthesia using either 0.5% tetracaine or 0.4% oxybuprocaine eye drops. The intervention group received pentadecapeptide BPC-157 (0.4 µg/eye) as eye drops, co-administered with the anesthetics. Other groups received the NOS inhibitor L-NAME (0.1 mg/eye) or the NOS substrate L-arginine (2 mg/eye), alone or in combination with BPC-157. Corneal sensitivity recovery was measured using a Cochet-Bonnet esthesiometer, corneal lesions were assessed via fluorescein staining, and tear volume was evaluated with the Schirmer test.
Results
BPC-157 administration had a full counteracting effect on the corneal anesthesia induced by tetracaine and oxybuprocaine, accelerating the recovery of corneal sensitivity and eliminating corneal lesions. This reversal effect occurred even in the presence of a nitric oxide synthase (NOS) blockade with L-NAME or supplementation with L-arginine. L-NAME application alone led to a longer duration of corneal insensitivity, increased corneal lesions, and decreased tear volume. Conversely, L-arginine alone shortened the duration of corneal insensitivity and counteracted corneal lesions and tear reduction, but only in the earlier period. When L-NAME and L-arginine were applied together, they antagonized each other's effects.
Regardless of the complex interactions within the
NOSsystem, the addition of BPC-157 consistently re-established a full counteraction against the topical anesthetic's effects, whether in the early or late course of anesthesia.
Key Findings
- BPC-157 (0.4 µg/eye) fully counteracted corneal anesthesia from 0.5% tetracaine and 0.4% oxybuprocaine.
- BPC-157's counteracting effect was maintained even with co-administration of NOS inhibitor L-NAME.
- NOS inhibitor L-NAME (0.1 mg/eye) prolonged corneal insensitivity and increased corneal lesions.
- NOS substrate L-arginine (2 mg/eye) shortened corneal insensitivity duration only in the early period.
- BPC-157 is suggested as a potential antidote to topical ophthalmic anesthetics.
Why It Matters
The findings suggest BPC-157 could serve as a potent antidote to topical ophthalmic anesthetics, rapidly restoring protective corneal sensation and mitigating side effects like lesions and dry eye. This has direct implications for ophthalmology, potentially reducing recovery time and improving safety after procedures requiring local anesthesia. For biohackers or individuals using peptides for healing, this highlights a specific application in ocular health and recovery. While this is an animal study, the clear, robust effect suggests a promising avenue for clinical translation. A future protocol could involve co-administering BPC-157 eye drops with anesthetics or applying them immediately post-procedure to accelerate recovery.
TitrateLab articles covering BPC-157
Written by TitrateLab, separately from the study summarized above.
